The companies will join forces to develop and commercialize ertugliflozin (PF-04971729), an oral sodium glucose cotransporter (SGLT2) inhibitor for type 2 diabetes which is about to begin phase 3 studies.
FORBES: What The Pfizer-Merck Diabetes Deal Teaches About Today's Pharma R&D